Sentiment-Signal
14,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 02.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 02.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 08.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 10.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 04.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 21.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 15.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 29.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financ |
| 09.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced, on O |
Stammdaten
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Unternehmen & Branche
| Name | enGene Holdings Inc. |
|---|---|
| Ticker | ENGN |
| CIK | 0001980845 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 362,2 Mio. USD |
| Beta | -0,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-01-31 | 10-Q | -29,752,000 | 0.44 | 337,113,000 | 281,546,000 | |
| 2025-10-31 | 10-K | -117,302,000 | 2.29 | 221,468,000 | 167,710,000 | |
| 2025-07-31 | 10-Q | -28,991,000 | 0.57 | 245,550,000 | 200,672,000 | |
| 2025-04-30 | 10-Q | -25,815,000 | 0.51 | 266,651,000 | 227,291,000 | |
| 2025-01-31 | 10-Q | -24,616,000 | 0.48 | 285,932,000 | 249,950,000 | |
| 2024-10-31 | 10-K | -55,142,000 | 1.46 | 311,173,000 | 272,612,000 | |
| 2024-07-31 | 10-Q | -14,148,000 | 0.32 | 266,879,000 | 230,329,000 | |
| 2024-04-30 | 10-Q | -14,984,000 | 0.38 | 273,528,000 | 242,966,000 | |
| 2024-01-31 | 10-Q | -10,711,000 | 0.46 | 93,421,000 | 62,385,000 | |
| 2023-10-31 | 10-K | -99,917,000 | 151.22 | 86,959,000 | 72,486,000 | |
| 2023-07-31 | 10-Q | -4,720,000 | 8.55 | -93,921,000 | ||
| 2023-04-30 | 10-Q | -5,282,000 | 9.30 | -89,238,000 | ||
| 2023-01-31 | 10-Q | -7,418,000 | 13.29 | -84,012,000 | ||
| 2022-10-31 | 10-K | -24,462,000 | 44.30 | 23,909,000 | -76,614,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.